|
Patent landscape, scope, and claims summary: |
United States Patent 10,080,734 (Autism, Neurodevelopmental Disorders) Claim Scope, Prior Art Risk, and Competitive Landscape
United States Patent 10,080,734 covers combination and monotherapy methods for treating autism or other neurodevelopmental disorders using (i) an isothiocyanate-functional surfactant and, in dependent claims, (ii) an NMDA-receptor antagonist and (iii) a TNF-α inhibiting agent. The claim set is drafted to capture broad classes of surfactants with isothiocyanate functionality (including protonated/deprotonated ionic forms, polymers/oligomers/dimers, and wide R-group variability), while also reciting broad “selected from” lists of TNF-α inhibitors and a defined NMDA antagonist (amantadine derivative). The enforceable core is likely centered on the specific chemical motif: an isothiocyanate group appended to a surfactant scaffold, used for neurodevelopmental indications, plus optional co-administration.
What claims does US 10,080,734 cover for autism treatment using isothiocyanate surfactants?
Core independent claim: Claim 1 is directed to a method for treating autism or other neurodevelopmental disorders by administering an effective amount of an isothiocyanate functional surfactant containing at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the surfactant.
Key dependent layers:
- NMDA-receptor antagonist add-on
Claim 2 adds an NMDA antagonist. Claim 3 narrows to 1-amino-3,5-dimethyladamantane (and pharmaceutically acceptable salts).
- TNF-α inhibiting agent add-on
Claim 4 adds TNF-α inhibiting agents, and Claim 5 narrows to: Lenalinomide, Thalidomide, L-Camosine, Infliximab, Etanercept, stem cell preparation, isomers, or pharmaceutically acceptable salts.
- Alternative independent chemistry framing via lysine derivative
Claim 8 is a second independent claim class focusing on a lysine derivative with α-amino nitrogen and ε-nitrogen, with an alkyl/alkanoyl substituent (≥ ~8 carbons) on the α-nitrogen and at least one isothiocyanate on the ε-nitrogen.
- Surfactant ionic/protonated structures
Claims 11-13 (and 18) define surfactant protonated/deprotonated forms with R2 = NCS and broad R-group enumerations, plus counters and polymeric/dimeric/oligomeric linkages.
Claim mapping table (what each claim element operationally requires)
| Claim |
Main active element required |
Indication |
Additional co-therapies |
| 1 |
Isothiocyanate functional surfactant; NCS attached to aliphatic/aromatic carbon |
Autism or neurodevelopmental disorders |
None |
| 2 |
Same as claim 1 |
Same |
+ NMDA receptor antagonist |
| 3 |
NMDA antagonist specifically 1-amino-3,5-dimethyladamantane |
Same |
+ TNF-α not required unless dependent |
| 4 |
Adds TNF-α inhibiting agent |
Same |
+ TNF-α agent |
| 5 |
TNF-α agent selected from list (lenalinomide, thalidomide, L-camosine, infliximab, etanercept, stem cell prep, isomers, salts) |
Same |
+ NMDA optional via claim chain |
| 6-7 |
Same as claims 4-5 but tied to claim 6 dependency chain |
Same |
+ TNF-α agent |
| 8 |
Lysine derivative with α-substituent (≥~8 carbons) + ε-isothiocyanate |
Same |
None |
| 9 |
Claim 8 + NMDA antagonist |
Same |
+ NMDA |
| 10 |
Claim 8 + TNF-α agent |
Same |
+ TNF-α |
| 11 |
Protonated surfactant scaffold with R2=NCS and broad R1/R3-R5 options incl. at least one C8-C25 substituent |
Same |
None |
| 12-13 |
Further restricts protonated structure variants |
Same |
None |
| 14-15 |
Claim 13 + NMDA antagonist; NMDA narrowed to 1-amino-3,5-dimethyladamantane |
Same |
NMDA present |
| 16-17 |
Claim 11 + TNF-α agent |
Same |
+ TNF-α |
| 18 |
Deprotonated surfactant structural claims, including counter cation concept |
Same |
None |
| 19 |
Claim 11 + additional surfactant (non-ionic/anionic/cationic/zwitterionic) |
Same |
Optional added surfactant |
| 20 |
Claim 11 with R1 constrained to specific groups; at least one of R3-R5 has C8-C25 |
Same |
None |
| 21 |
Claim 18 (per chain) variant with counter cation specified and same R constraints |
Same |
None |
How broad are the isothiocyanate surfactant claims in US 10,080,734 (R-group and ionic-form coverage)?
Breadth levers that increase potential infringement reach:
- Functional definition in Claim 1: “isothiocyanate functional surfactant” with at least one isothiocyanate group associated with aliphatic/aromatic carbon. This is not restricted to a single scaffold, enabling arguments that many NCS-bearing amphiphiles could fall within the claim if they behave as surfactants.
- Structural Markush breadth in Claims 11-13 and 18:
- R2 = NCS is fixed (strong technical anchor).
- R1 and R3-R5 are described with extensive allowable substitutions, including alkyl/cycloalkyl/heterocycloalkyl/aryl/alkaryl/aralkyl/alkoxy/alkanoyl/aro yl/alkenyl/alkynyl/cyano, with ranges from ~1 to ~25 carbons.
- A C8 to C25 proviso is applied to at least one of R3-R5 in several variants, aligning with surfactant hydrophobic tail length typical of micelle-forming amphiphiles.
- Polymeric linkage allowance: “linkage to a dimer/oligomer/polymer” expands potential coverage to larger assemblies or conjugates.
- Ionic states: separate attention to protonated and deprotonated forms and counter cations suggests the patentee intended coverage over salt forms and charged species used in formulation.
Potential narrowing elements that can limit infringement:
- The NCS location/association requirement: the isothiocyanate must be “associated with” aliphatic and/or aromatic carbon atoms of the surfactant; if an accused compound uses a different linkage (e.g., isothiocyanate as a detached small molecule co-formulant rather than covalently part of the surfactant), the patentee still tries to capture “functional surfactant” but would likely face factual disputes.
- Surfactant requirement: claims require a “surfactant” (or surfactant salt/ion form). A non-surfactant NCS derivative is outside claim scope even if it contains NCS.
- C8-C25 proviso: for claims that incorporate it (notably Claim 11 variants), tail length constraints can exclude short-chain NCS amphiphiles.
Which co-therapies are claimed in US 10,080,734 (NMDA antagonists and TNF-α inhibitors) and how does selection affect infringement?
NMDA-receptor antagonist (claims 2-3 and 9, 14-15)
- Broad recitation in dependent claim 2/9/14: “administering a NMDA-receptor antagonist”
- Single-defined narrow species in claim 3 and claim 15: 1-amino-3,5-dimethyladamantane.
Infringement implication:
If the accused regimen uses a different NMDA antagonist class (e.g., memantine-like agents), literal infringement of the narrower dependent claims is less likely, but claim 2/9/14-style coverage could still be asserted depending on how “NMDA-receptor antagonist” is interpreted and whether the compound is an NMDA antagonist in pharmacology.
TNF-α inhibiting agents (claims 4-5, 6-7, 10, 16-17)
The TNF-α list is unusually broad by modality:
- Small molecules and derivatives: Thalidomide, Lenalinomide, L-Camosine
- Biologics: Infliximab, Etanercept
- Stem cell preparation and isomers and salts
Infringement implication:
A co-administered regimen using any listed TNF-α inhibiting agent could trigger dependent claim infringement if the surfactant/NCS element is present and the indication is within claim framing.
What lysine-derivative formulation pathway does US 10,080,734 add beyond surfactant generality?
Claim 8 creates a second independent chemical framing that may be easier to design-around than the pure functional definition in Claim 1, because it imposes a specific scaffold requirement:
- Lysine derivative with:
- α-nitrogen bearing an alkyl/alkanoyl substituent of at least approximately 8 carbons
- ε-nitrogen bearing at least one isothiocyanate functional group
This structure-based claim can provide the patentee with a tighter pivot in litigation: rather than having to prove “isothiocyanate functional surfactant” across many scaffolds, it can argue infringement through a defined lysine-based amphiphile chemistry.
What patentability and validity risks arise from the claim structure of US 10,080,734?
Even without the patent’s prosecution history, the claim drafting itself creates predictable validity attack paths.
1) Obviousness risk: broad combination therapy logic
The dependent claims pair:
- neurodevelopmental treatment using NCS-containing surfactants, with
- co-administration of NMDA antagonists, and
- co-administration of TNF-α inhibitors.
NMDA antagonism and TNF-α modulation are established therapeutic concepts across inflammatory and neuropsychiatric contexts. A challenger can argue that selecting known co-therapies for autism/neurodevelopmental disorders is a routine optimization, making the combination obvious if the surfactant aspect is not clearly differentiated over prior NCS amphiphiles and prior autism combination rationale.
2) Enablement and written description pressure from Markush breadth
Claims 11-21 include extensive R-group permutations (and polymer/dimer/oligomer linkages) combined with a fixed NCS motif and ionic forms. Such breadth can be attacked as lacking sufficient disclosure to enable the full scope, especially for:
- large hydrophobes (up to C25),
- diverse aromatic/heteroaryl substitutions,
- countercation variability,
- polymeric/dimeric/oligomeric linkages.
3) Indefiniteness or claim construction disputes around “surfactant” and “associated with”
Claims 1 and 11 hinge on:
- whether a compound qualifies as a “surfactant” (a functional property),
- what “associated with” means for the isothiocyanate group attachment,
- whether ionic/protonated/deprotonated “forms” map to specific chemical species under claim construction.
4) Prior art NCS amphiphiles as “close” references
If prior art exists describing:
- NCS-bearing amphiphiles,
- isothiocyanate-functional ionic surfactants,
- NCS-modified amphiphiles used for biological delivery,
then Claim 1’s functional breadth becomes vulnerable unless the patent ties autism treatment to a specific unexpected property of that surfactant class.
How can a generic or competitor design around US 10,080,734 (literal and practical barriers)?
Primary design-around levers
-
Remove NCS from the surfactant scaffold
Keep NCS as a separate therapeutic or prodrug not covalently part of an amphiphile.
-
Use a non-isothiocyanate functional group
Swap NCS for related chemotypes (e.g., thiocarbamates, isocyanates, nitriles) that may not meet the NCS requirement.
-
Avoid the lysine-derivative scaffold of Claim 8
Use different linker chemistry that does not meet α/ε nitrogen substitution requirements.
-
Avoid the C8-C25 proviso
For claims incorporating tail length constraints (notably Claim 11 variants), design with shorter hydrophobic tails or a different distribution that defeats the “at least one of R3-R5” C8-C25 requirement.
-
Avoid ionic “protonated/deprotonated form” mapping
If the accused compound uses different salt/ion architectures, the patentee may still argue equivalence, but literal overlap may narrow.
Combination regimen design-around (dependent claims)
- If an accused therapy uses the same NCS surfactant but excludes NMDA antagonists or TNF-α inhibitors, it may avoid dependent claims 2-7/9-10/14-17 while still potentially implicating Claim 1 or Claim 8.
- If the regimen uses NMDA antagonist but not the specified TNF-α agents list, it may avoid claims that require those TNF-α selections.
What does US 10,080,734 likely claim-protect commercially (formulation and dosing strategy implications)?
The patent reads like a method-of-use umbrella tethered to an active chemical class. Commercial protection therefore likely attaches to:
- any therapeutic administration of NCS-functional surfactants for autism/neurodevelopmental indications;
- co-administration strategies pairing with NMDA antagonism and TNF-α inhibition.
Because claims are method-based, the strongest enforcement path is often:
- the prescribed regimen and drug labels used by a sponsor,
- clinical protocol wording,
- any compounding instructions showing the NCS amphiphile’s identity.
Key takeaway: the infringement magnet is NCS attached to an amphiphile-like scaffold plus autism treatment
Across claims, the patentee’s enforcement thesis likely is:
- NCS-functional surfactants (including ionic/protonated/deprotonated variants and lysine derivatives) used to treat autism/neurodevelopmental disorders,
- optionally in combination with NMDA receptor antagonists (explicitly including 1-amino-3,5-dimethyladamantane) and TNF-α inhibitors from a broad list.
Key Takeaways
- US 10,080,734 is built around one technical anchor: isothiocyanate (NCS) functionality integrated into a surfactant (and ionic/salt forms), plus autism/neurodevelopmental treatment methods.
- Dependent claims broaden enforcement through combination therapy with NMDA antagonists and TNF-α inhibitors, including biologics and small molecules.
- Markush breadth in surfactant substitutions (R-group variability, countercations, polymeric/dimeric/oligomeric linkages) increases reach but also raises classic enablement/written description and claim construction vulnerabilities.
- Practical design-around focuses on: removing NCS from the surfactant scaffold, using non-lysine scaffolds, avoiding the C8-C25 proviso in tail length-constrained variants, or omitting NMDA/TNF-α co-therapies to evade dependent claims.
FAQs
-
Does US 10,080,734 cover autism treatment using any isothiocyanate-containing drug?
No. The claims require an isothiocyanate functional surfactant (or a lysine-derivative with defined NCS placement and substituent pattern) used as a method of treatment for autism/neurodevelopmental disorders.
-
Can a competitor avoid infringement by using a different NMDA antagonist than 1-amino-3,5-dimethyladamantane?
It may reduce risk for the narrower dependent claims that specifically recite 1-amino-3,5-dimethyladamantane, but the broader NMDA antagonist-dependent claims may still be implicated if the competitor uses an NMDA receptor antagonist.
-
Which TNF-α inhibitors are explicitly covered by US 10,080,734?
The dependent claims include Lenalinomide, Thalidomide, L-Camosine, Infliximab, Etanercept, stem cell preparations, isomers, and pharmaceutically acceptable salts.
-
Do the surfactant claims cover both protonated and deprotonated forms?
The claim set includes specific protonated-form structures (claims 11-13) and a deprotonated-form structural claim (claim 18), with countercation concepts.
-
Is the lysine-derivative claim (claim 8) an alternative independent route for infringement?
Yes. Claim 8 defines a lysine derivative with defined NCS placement and a minimum C8 substitution on the α-nitrogen, giving a second chemical scaffold route beyond the general surfactant definition in claim 1.
References (APA)
- Claims text provided in the prompt for United States Patent 10,080,734.
More… ↓
⤷ Start Trial
|
